Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1964559

Ambit Biosciences Corporation - Product Pipeline Review - H2 2011

Description:

Ambit Biosciences Corporation – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Ambit Biosciences Corporation - Product Pipeline Review - H2 2011” provides data on the Ambit Biosciences Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ambit Biosciences Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Ambit Biosciences Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ambit Biosciences Corporation - Brief Ambit Biosciences Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ambit Biosciences Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ambit Biosciences Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ambit Biosciences Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Ambit Biosciences Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ambit Biosciences Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ambit Biosciences Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ambit Biosciences Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ambit Biosciences Corporation and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Ambit Biosciences Corporation; Ambit Biosciences Corporation - Key Therapeutics; Ambit Biosciences Corporation - Pipeline Overview and Promising Molecules; Ambit Biosciences Corporation - News; Ambit Biosciences Corporation - Latest Updates; Ambit Biosciences Corporation - Pipeline; Ambit Biosciences Corporation - Discontinued/Dormant Projects

Contents:

List of Tables
List of Figures
Ambit Biosciences Corporation Snapshot
Ambit Biosciences Corporation Overview
Key Information
Key Facts
Ambit Biosciences Corporation – Research and Development Overview
Key Therapeutic Areas
Ambit Biosciences Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ambit Biosciences Corporation – Pipeline Products Glance
Ambit Biosciences Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ambit Biosciences Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Ambit Biosciences Corporation – Drug Profiles
AC220
AC220 + Daunorubicin + Cytarabine
AC430
AC480
AC480 + Docetaxel
AC480_
AC710
PanHER IV
Ambit Biosciences Corporation – Pipeline Analysis
Ambit Biosciences Corporation – Pipeline Products by Therapeutic Class
Ambit Biosciences Corporation – Pipeline Products by Route of Administration
Ambit Biosciences Corporation – Recent Pipeline Updates
Ambit Biosciences Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 20, 2010: Ambit Biosciences Initiates Phase I Clinical Trials For AC430
Dec 20, 2010: Ambit Biosciences Initiates Phase I Clinical Trials For AC480
Dec 18, 2009: Ambit Biosciences and Astellas Enter Strategic artnership To Research, Develop And Commercialize FLT3 Kinase Inhibitors in Multiple Indications
Jun 13, 2011: Ambit Biosciences And Astellas Pharma Announce Interim Data From Phase II Trial Of AC220
Dec 11, 2009: Ambit Biosciences Initiates Phase II Clinical Trial Of AC220 For The Trearment Of Acute Myeloid Leukemia
Apr 10, 2007: Ambit Biosciences Begins Dosing Patients In Phase I Clinical Trial Of Lead Kinase Inhibitor AC220
Dec 09, 2008: Ambit Biosciences Presents Data On Its Targeted Cancer Therapeutic AC220 For Acute Myeloid Leukemia
Jun 09, 2011: Ambit Biosciences And Astellas Announce Upcoming Presentation Of AC220 Data At 16th Annual Congress Of European Hematology Association
Dec 08, 2007: Ambit Biosciences Presents Data On AC220 In Acute Myeloid Leukemia At American Society For Hematology Conference
Dec 07, 2009: Ambit Biosciences Corporation Announces Two Poster Presentations Characterizing the Effects of AC220 in Preclinical Models of Acute Myeloid Leukemia at ASH Conference
Dec 07, 2009: Ambit Biosciences Corporation Announces Two Poster Presentations Characterizing the Effects of AC220 in Preclinical Models of Acute Myeloid Leukemia at ASH Conference
Dec 07, 2009: Ambit Biosciences Corporation Presents Phase I Clinical Results Of AC220 In Patients With Acute Myeloid Leukemia At ASH Conference
Dec 07, 2009: Ambit Biosciences Presents Phase I Clinical Results Of AC220 For Acute Myeloid Leukemia At ASH Conference
Financial Deals Landscape
Ambit Biosciences Corporation, Deals Summary
Ambit Biosciences Corporation, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Ambit Biosciences Secures $30 Million In Series D-2 Financing
Ambit Biosciences Secures $15 Million In Financing Round
Ambit Biosciences Secures $6.4 Million In Series E Venture Financing
Ambit Biosciences Secures $49.3 Million In Series D Financing
Ambit Biosciences Secures Additional $10 Million In Series C Financing
Ambit Biosciences Secures $21 Million In Series C Financing
Partnerships
Ambit Biosciences Enters Into Co-Development Agreement With Astellas Pharma
Ambit Extends Agreement With Bristol-Myers
Ambit Biosciences Enters Into An Agreement With Cephalon
Ambit Biosciences Enters Into Co Development Agreement With Pfizer
Ambit Biosciences Enters Into Co-Development Agreement With GlaxoSmithKline
Ambit Biosciences Enters Into Collaboration Agreement With Bristol-Myers Squibb
Ambit Biosciences Enters Into An Agreement With Roche Holding
Licensing Agreements
Ambit Biosciences Expands Licensing Agreement With Bristol-Myers Squibb
Asset Transactions
DiscoveRx Acquires KINOMEscan Kinase Screening Services Division From Ambit Biosciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Ambit Biosciences Corporation – Pipeline by Therapy Area and Indication, H2 2011
Ambit Biosciences Corporation – Pipeline by Stage of Development, H2 2011
Ambit Biosciences Corporation – Monotherapy Products in Pipeline, H2 2011
Ambit Biosciences Corporation – Combination Treatment Modalities in Pipeline, H2 2011
Ambit Biosciences Corporation - Phase II, H2 2011
Ambit Biosciences Corporation - Phase I, H2 2011
Ambit Biosciences Corporation - Pipeline By Therapeutic Class, H2 2011
Ambit Biosciences Corporation – Pipeline By Route of Administration, H2 2011
Ambit Biosciences Corporation – Recent Pipeline Updates, H2 2011
Ambit Biosciences Corporation, Other Locations
Ambit Biosciences Corporation, Deals Summary
Ambit Biosciences Secures $30 Million In Series D-2 Financing
Ambit Biosciences Secures $15 Million In Financing Round
Ambit Biosciences Secures $6.4 Million In Series E Venture Financing
Ambit Biosciences Secures $49.3 Million In Series D Financing
Ambit Biosciences Secures Additional $10 Million In Series C Financing
Ambit Biosciences Secures $21 Million In Series C Financing
Ambit Biosciences Enters Into Co-Development Agreement With Astellas Pharma
Ambit Extends Agreement With Bristol-Myers
Ambit Biosciences Enters Into An Agreement With Cephalon
Ambit Biosciences Enters Into Co Development Agreement With Pfizer
Ambit Biosciences Enters Into Co-Development Agreement With GlaxoSmithKline
Ambit Biosciences Enters Into Collaboration Agreement With Bristol-Myers Squibb
Ambit Biosciences Enters Into An Agreement With Roche Holding
Ambit Biosciences Expands Licensing Agreement With Bristol-Myers Squibb
DiscoveRx Acquires KINOMEscan Kinase Screening Services Division From Ambit Biosciences

List of Figures
Ambit Biosciences Corporation – Pipeline by Therapy Area and Indication, H2 2011
Ambit Biosciences Corporation – Pipeline by Stage of Development, H2 2011
Ambit Biosciences Corporation – Monotherapy Products in Pipeline, H2 2011
Ambit Biosciences Corporation – Combination Treatment Modalities in Pipeline, H2 2011
Ambit Biosciences Corporation – Pipeline By Therapeutic Class, H2 2011
Ambit Biosciences Corporation – Pipeline By Route of Administration, H2 2011

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Thursday, May 23, 2013
5:58:24 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Ambit Biosciences Corporation - Product Pipeline Review - H2 2011

Web Address

http://www.researchandmarkets.com/reports/1964559

Office Code

OC8DIQSOLSPUPY

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Thursday, May 23, 2013
5:58:24 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Ambit Biosciences Corporation - Product Pipeline Review - H2 2011

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)